MT Newswires5d agoneutral
UBS Adjusts Price Target on Iovance Biotherapeutics to $8 From $7, Maintains Neutral RatingNotícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
106last 24h
3125last 7d
511● bullish (7d)
311● bearish (7d)
227publishers
Stocktwits40d agoneutral
IOVA Stock Hits Over 2-Year Highs - Why Iovance Raised Its FY2026 Revenue OutlookInvesting.com40d agobullish
Iovance shares jump in premarket as raised outlook clears consensus views